Business · 14/06/2019Updated: 10/17/2026 · 1 min read
FDA Withdraws Approval of 12 Hospira-Submitted Abbreviated New Drug Applications
Summary
The US Food and Drug Administration (FDA) has withdrawn the approval of 12 abbreviated new drug applications (ANDAs) submitted by Hospira, Inc. and other applicants, following notification that the corresponding drug products are no longer commercially available.
Original source language: Federal Register — Food and Drug AdministrationOpen original release →